Polyrizon reports promising results demonstrating successful internasal delivery of its innovative hydrogel formulation for cns therapeutics

Ra'anana, israel, june 12, 2025 (globe newswire) -- polyrizon ltd. (nasdaq: plrz) (the “company” or “polyrizon”), a biotechnology company developing intranasal drug delivery systems, today announced encouraging preclinical results from a recent study evaluating its proprietary hydrogel-based trap & target (t&t) platform.
PLRZ Ratings Summary
PLRZ Quant Ranking